Subsequently, the PRJEB25780 cohort, comprising of 45 individuals diagnosed with advanced stomach cancer receiving PD-L1 inhibitor therapy, was employed to determine the effectiveness of the risk signature associated with calcium extrusion in accurately predicting the outcomes of immunotherapy. This evidence concerns the gene CD274 and gastric neoplasm.